Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Advanced Cancer 5Neoplasms 2Melanoma 2Skin Neoplasms 1Malignancies Multiple 1Carcinoma, Non-Small-Cell Lung 1Advanced Gastric Cancer 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × linrodostat × Clear all
NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
229 enrolled 21 charts

Advanced Cancer

NCT02996110 2022-12-19

FRACTION-RCC

Bristol-Myers Squibb

Phase 2 Completed
182 enrolled 23 charts

Advanced Cancer

NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed
20 enrolled

Advanced Cancer

NCT03792750 2022-02-28

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
12 enrolled 26 charts

Advanced Cancer

NCT03192943 2019-04-01

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Bristol-Myers Squibb

Phase 1 Completed
11 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡